Researchers have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6). Researchers at The University of Texas ...

“Immunotherapy with checkpoint inhibitors is currently the best therapeutic strategy for treatment of multiple cancer types. However, durable remission rate with checkpoint inhibitor monotherapy ...

In a recent study posted to Research Square*, researchers reported that plasma interleukin (IL)-6 levels in patients with acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 ...

However, imbalances of IL-6 — too much or too little — can cause disease, even in the absence of infection. Excess IL-6 is central to the pathogenesis of inflammatory reactions like rheumatoid disease ...

Covid-19 denotes coronavirus disease 2019, CT computed tomography, ICU intensive care unit, MIS-C multisystem inflammatory syndrome in children, ND not determined, PASC postacute sequelae of Covid-19, ...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company ...

Exposures before birth and in early life, including paternal smoking and maternal obesity, are key predictors of lung health ...

HOUSTON ― Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the ...